Evan Leitner

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.

Cooley advised the underwriters of Silvaco, a leading provider of technology computer-aided design (TCAD), electronic design animation (EDA) software, and session initiation protocol (SIP) solutions that enable semiconductor design and artificial intelligence through software and innovation, on its $114 million initial public offering.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised the underwriters in ADC Therapeutics’ $60 million follow-on offering. Jefferies acted as sole book-running manager for the offering. ADC Therapeutics is a commercial-stage, oncology-focused biotechnology company involved in the development of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. Partners Richard Segal and Div Gupta led the Cooley team.